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The objective of this study was to evaluate quality parameters of magistral topical solutions containing minoxidil (A, B and C), 
comparing the results with the ones obtained for the industrial formulation. Organoleptic tests, evaluation of the pH and density, 
centrifuge test, drug content determination, comparison of indicated dosage and in vitro follicular penetration of minoxidil were 
performed. Regarding the organoleptic properties, differences in color and viscosity were observed between the magistral 
(composed of minoxidil sulfate) and the industrial formulations (composed of minoxidil base). For pH values, the magistral solutions 
presented considerably more acidic pH, compared to the industrial sample. For the density test, the samples with the highest ethanol 
percentages (B and C) presented lower density. In the centrifuge test, none of the samples showed changes. Considering the drug 
content test, only the industrial sample and the magistral sample C showed drug percentage within the expected (90-110%), 
indicating lack of correction factor determination by the magistral pharmacies. Furthermore, it was observed that the dosage 
indicated by the magistral pharmacies do not correspond to the dose indicated by the industry, being significantly lower. All topical 
solutions tested presented hair follicle penetration of minoxidil, without statistical difference. The results indicate that there is a 
failure in the magistral pharmacies regarding the production and the indication of dosage of minoxidil topical solutions. 
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Introduction  
 
Alopecia, popularly known as baldness, is characterized by 
the fall of the hair. It is a chronic inflammatory 
dermatological disease that affects hair follicles [1]. Its 
etiology and development are not fully known, however, it 
may be linked to genetic, environmental and/or autoimmune 
disorders. Although it has few harmful effects on the body, 
alopecia can lead to psychological problems such as anxiety 
and depression. Nowadays, alopecia affects women almost as 
much as men. Different types of alopecia develop different 
characteristics and need specific treatments, since they 
present different causes. Among the most common acquired 
alopecia, the androgenetic alopecia can be mentioned, which 
is caused by genetic factors as well as androgen hormones and 
their metabolites [1,2,3,4]. 
Minoxidil is one of the most used drugs to treat alopecia. It 
was initially indicated as a hypotensive agent for patients with 
refractory oral hypertension. In the treatment of alopecia, it is 
used as a topical solution acting by a vasodilatory effect and 
by keeping the hair follicle in the anagen phase longer [3,4,5]. 
Combined use of minoxidil with other drugs enhances its 
effect and brings better results for patients undergoing 
treatment [1]. 
Topical solutions containing minoxidil can be obtained from 
magistral pharmacies, allowing the customization of the drug 
concentration and the formulation components according to 
the patient´s needs, besides presenting lower costs when 
compared to the industrial product. However, considering 
that the magistral pharmacies do not perform as many quality 
control assays in their products as the pharmaceutical 
industries, magistral formulas may present quality deviations 
affecting their therapeutic effects as well as their safety [6,7]. 
For liquid formulations, appearance, organoleptic 
characteristics, pH and volume determinations should be 
performed for each formula produced by the magistral 
pharmacy, while the drug content determination  
should be evaluated for at least one formulation every three 
months [8]. 
In view of the exposed, this study aimed to evaluate the 
quality parameters of minoxidil topical solutions from 
magistral pharmacies, through physicochemical assays, 
evaluation of the indicated dose as well as in vitro drug 
follicular penetration, comparing the results with the ones 
obtained for the reference industrial product. 
Materials and Methods 
Materials 
 
Magistral topical solutions containing 5% of minoxidil were 
purchased from three magistral pharmacies located in Rio 
Grande do Sul, Brazil, and identified as A, B and C. The 
industrial reference medication (Aloxidil®, Theraskin, Brazil) 
was purchased from a local drugstore. Minoxidil base was 
obtained from Fagron (Brazil). The samples were kept in the 
original packaging at room temperature and protected from 
light and humidity until the tests were performed. The other 
materials used were analytical grade methanol (Qhemis, 
Brazil) propylene glycol (Delaware, Brazil) and purified 
water. 
Physicochemical characterization 
 
Magistral and industrial solutions were first evaluated 
regarding their organoleptic properties, resistance to 
centrifugation, pH and mass density according to Brazilian 
pharmacopoeia and the national health surveillance 
guidelines [9,10,11]. All analysis were performed in 
triplicate.  
The homogeneity, color, transparency, odor and apparent 
viscosity of the magistral and industrial samples were 
evaluated by visual appearance. Regarding the resistance to 
centrifugation, the solutions were placed in falcon tubes and 
centrifuged at 3000 rpm for 30 minutes. After that, they were 
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visually analyzed, checking whether there were changes. 
Such test is preconized as pre-stability determination [10]. 
For pH determination, the topical solutions were placed in 
contact with a calibrated electrode, without previous dilution. 
Aiming determination of mass density, the relative density 
was determined using a 5 mL pycnometer. Initially, the 
formulations and a sample of purified water were set at a 
temperature of 25 °C. The empty pycnometer was weighed 
and then filled with purified water and weighed again. The 
process was repeated with the samples. To determine the 
mass density, the water density at 25 °C and the relative 
density determined were taken into account. 
Then, the drug content was determined. For the quantification 
of minoxidil in the topical solutions, the ultraviolet 
spectrophotometry method was used, measuring the 
absorbance at 285 nm, according to a previously validated 
method [5]. 
To confirm the suitability of the method, the linearity in the 
range from 3-15 µg/mL was determined, as well as the 
method specificity, which was assessed evaluating the 
placebo (solution containing all adjuvants except for the 
drug). To prepare the samples, the minoxidil base substance 
was diluted in methanol (first dilution) and purified water 
(second dilution). For the magistral and industrial topical 
solutions, 1.4 mL of the samples were transferred into a 100 
mL volumetric flask containing 10 mL of methanol, which 
was placed in the ultrasound bath for 5 minutes. After that, 
the volume was adjusted with purified water. A second 
dilution in water was performed to reach a concentration of 7 
μg/mL of minoxidil. The obtained concentration values of the 
samples were compared to the theoretical concentration, 
obtaining the value of drug content in percentage. The 
samples considered approved were the ones presenting from 
90% to 110% of the labeled amount of minoxidil [12]. 
 
Comparison of indicated dosage 
 
For comparison of the indicated dosage of the formulations, 
the volumes corresponding to the dosage indicated by the 
pharmacies and by the medication package insert of the 
industrial product were determined in triplicate. Thus, for the 
magistral samples, the amount of 20 drops was weighed from 
a vertical drip (considered the most suitable for dropper 
bottles) as well as from a horizontal drip (more easily 
performed by the patients). For the industrial sample, the 
amount of 6 jets was weighed. The mass value was converted 
to volume using the mass density previously determined. 
In vitro follicular penetration of minoxidil 
 
Pork ears, obtained from a local slaughterhouse, were 
sanitized with sodium lauryl sulfate solution (0.5%) and the 
hair was removed with a razor blade, gently applied to the 
skin surface. Then, the outermost layer of the skin was 
removed from the cartilage with the aid of the scalpel, and cut 
into circles of between 0.06 cm and 0.11 cm thick. The skin 
samples were frozen at -4°C in aluminum foil until use, which 
did not exceed 2 months. 
Follicular penetration of minoxidil from different topical 
solutions were evaluated using Franz diffusion Cell in 
triplicate. The skin sample was placed between the donor and 
the receptor compartments. The receptor compartment was 
filled with 18 mL of purified water. In the donor 
compartment, 2 mL of minoxidil topical solution was added. 
The apparatus was maintained at 32 °C and under stirring for 
5 h. After that, the amount of minoxidil that remained in the 
hair follicles was assessed using differential tape stripping 
[13]. The skin sample was removed from the Franz cell and 
the stratum corneum was removed with the aid of 15 adhesive 
tapes. The follicular content was then removed by applying a 
drop of cyanoacrylate glue. A piece of tape was placed over 
the glue and it was slightly pressed for 5 min. The tape was 
then removed and the dried glue layer adhered to the tape was 
transferred to a glass tube from which minoxidil was 
extracted by the addition of 5 mL of methanol with ultrasound 
bath for a period of 40 min. The drug content was analyzed at 
285 nm by UV spectrophotometer. The amount of minoxidil 
that was kept in the hair follicles was calculated by a standard 
curve obtained with minoxidil base solubilized in methanol 
(3, 5, 7, 10 e 15 µg/mL). An experiment applying the placebo 
(solution containing all adjuvants except for the drug) was 
also performed. 
Statistical analysis 
 
The statistical analysis was performed by analysis of 
variance, followed by Dunnett’s test, when a significant 
difference was detected (α=0.05). 
Results and Discussion  
Composition of formulations 
 
The compositions of the formulations evaluated in this study 
are described in Table 1. The industrial topical solution, 
considered reference in the Brazilian market, is composed of 
minoxidil base, propylene glycol (co-solvent) and a 
hydroalcoholic vehicle. The active minoxidil in base form is 
chemically presented as 3-hydroxy-2-imino-6-piperidin-1-
ylpyrimidin-4-amine (C9H15N5O), with a molecular weight of 
209.5 g/mol, CAS of 38304-91-5 and DCB number of 05980. 
It is a crystalline, off-white solid, soluble in acid and 
propylene glycol solutions, poorly soluble in alcohols and 
insoluble in water, acetone and alkaline solutions [14,15]. 
 
Table 1: Composition of minoxidil topical solutions according to 
the manufacturer’s declaration (A= magistral sample A, B= 
magistral sample B, C= magistral sample C, Reference = industrial 
reference product). Water is used as solvent to reach 100%. 
Sample Minoxidil 
Propylen
e glycol 
Ethano
l 
A 5%   
(minoxidil sulfate) 
3% 30% 
B 5%   
(minoxidil sulfate) 
5% 70% 
C 5%   
(minoxidil sulfate) 
10% 50% 
Reference 5 %   
(minoxidil base) 
NI* NI* 
* NI:  Not informed  
 
The magistral solutions are formulations composed of 
minoxidil sulfate, propylene glycol and a hydroalcoholic 
vehicle. According to the certificate of analysis, minoxidil 
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sulfate is a salt (C18H30N10O2.H2SO4), presenting molecular 
weight of 516.58 g/mol, CAS of 83701-22-8 and DCB 
number of 09761. Due to salt formation, the solubility of the 
active is favored. 
Evaluation of physicochemical characteristics 
 
The magistral and the industrial samples were evaluated 
according to their physicochemical properties (Table 2). 
Regarding the color, the reference sample was light yellow, 
while the magistral samples were colorless. This may be 
justified by the minoxidil in the base form used in the 
industrial solution, which is a slightly yellowish powder. The 
minoxidil sulfate, on the other side, presents a white color. 
The magistral and the industrial solutions were homogeneous 
and clear, but the reference industrial product presented air 
bubbles, which can be due to the spray present in the 
industrial packing, while the magistral solutions are placed in 
dropper bottles. 
 
Table 2: Physicochemical properties of the minoxidil topical solutions (A= magistral sample A, B= magistral sample B, C= magistral sample C, 
Reference = industrial reference product) 
Tests A B C Reference 
Color Colorless Colorless Colorless Light yellow 
Homogeneity Homogeneous Homogeneous Homogeneous 
Homogeneous 
with air bubbles 
Transparency Clear Clear Clear Clear 
Odor 
Ethanol and 
propylene glycol 
Ethanol Ethanol 
Ethanol and 
propylene glycol 
Viscosity Low Low Low Low to medium 
pH 2.61± 0.02 2.80 ± 0.02 2.78 ± 0.01 8.04 ± 0.02 
Density (g/mL) 0.9813 ± 0.001 0.9103 ± 0.0008 0.9208 ± 0.0006 1.0039 ± 0.0017 
Resistance to 
centrifugation 
No changes No changes No changes No changes 
Minoxidil 
content (%) 
82.27 ± 0.33 82.48 ± 0.45 97.63 ± 0.12 98.19 ± 5.90 
 
 The magistral sample A presented an odor which is 
characteristic of ethanol and a slight propylene glycol odor, 
while for the magistral samples B and C only ethanol odor 
was noticed, which is due to the higher ethanol percentage. 
Regarding the industrial sample, odor of propylene glycol and 
ethanol were noticed. Such solution, since it is composed of 
minoxidil base, supposedly requires a greater amount of 
propylene glycol for active solubilization, when compared to 
the magistral formulations that use minoxidil sulfate [15]. 
Also, a higher viscosity of the industrial solution was 
observed compared to the magistral samples, which indicates 
a higher amount of propylene glycol, since such substance is 
a slightly viscous raw material. 
Regarding the pH of the solutions, it is noted that the 
magistral samples A, B and C presented acidic pH, 
significantly lower than the reference sample, which 
presented basic pH, due to the structural difference in the 
active molecule used in the different formulas. Due to the low 
pH of the magistral products, some adverse reactions may 
appear throughout the treatment, such as dermatitis, peeling 
and irritation [16]. Minoxidil is stable above pH 2.0 [17]. 
Since the monoxidil topical solutions are hydroalcoholic, the 
determination of density may indicate the amount of ethanol 
in the formulation. All magistral samples presented 
significantly lower density than the industrial product. It can 
be seen that magistral sample B, with the highest ethanol 
content, presented the lowest density, the opposite being 
observed for the magistral solution A. Since the amount of 
ethanol in the industrial product is not known, it is assumed, 
by the density presented, that the ethanol concentration in this 
product is lower than in the magistral formulas. Moreover, the 
density value observed for the reference product is also 
probably related to a greater amount of propylene glycol in 
such sample, which has a density of around 1.035 [9]. 
Regarding the resistance to centrifugation, none of the 
samples showed signs of instability at the end of the test, 
indicating that the products have a tendency to remain 
physically stable throughout storage due to the addition of 
solvents and co-solvents. The centrifugation test is used to 
predict possible formulation instabilities such as 
precipitation, which could occur in this study due to incorrect 
solubilization of the drug and formation of precipitates [11]. 
The analytical method used to evaluate the minoxidil content 
in the topical solutions presented adequate linearity and 
specificity, since a solution composed of water, ethanol and 
propylene glycol showed no absorbance at 285 nm and 
correlation values greater than 0.99 were observed. The 
industrial samples and the magistral sample C showed a 
percentage of around 98% of the theoretical minoxidil 
concentration, without significant differences, while for the 
magistral samples A and B significant lower percentages 
were found (close to 80%). According to the American 
pharmacopeia, only the industrial product and the magistral 
sample C presented concentration of minoxidil within the 
specification [12]. 
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When using a salt or an ester of a raw material instead of its 
base, the correction factor should be determined. Therefore, 
it can be suggested that such correction during the weighting 
process of the active was not performed by the magistral 
pharmacies A and B. Other quality deviation factors may also 
have led to the low active concentration in the solutions, such 
as weighing error, lack of balance calibration, improper 
storage of raw materials, substance degradation, among 
others [16]. 
 
 
Comparison of indicated dosage 
 
The volume of solution to be applied on the scalp was 
evaluated according to the dosage indicated by the 
manufacturer in drops (using the vertical and horizontal 
dropper) or in jets. The results are described in Figure 1. 
According to the information found in the package leaflet of 
the reference product, 6 jets of the drug solutions should be 
applied, which corresponded to around 1 mL. For the 
magistral samples, it was followed the indication of the 
magistral pharmacies which manipulated the formulas, where 
the usual dose was 20 drops/day. It was observed that, in the 
horizontal position, all magistral products led to higher 
solution volumes compared to the vertical position, but both 
the horizontal and vertical positions lead to significant lower 
volumes compared to the volume indicated by the reference 
product package leaflet. 
When evaluating the amount of minoxidil at each dosage 
considering the concentration of active described on the 
labels (50 mg/mL), 6 jets of the industrial product correspond 
to around 50 mg of minoxidil, while 20 drops of the magistral 
solutions correspond to around 30 mg of minoxidil. The 
indicated dosage of the industrial product corresponds to a 
considerable greater amount of drug in relation to the dosage 
indicated by the pharmacies. It should also be considered that 
the package leaflet describes that the industrial reference 
product can be applied up to 2 times a day. The lower dosage 
indication for the magistral minoxidil topical solutions, 
besides a lower drug content, compared to the reference 
industrial product, can lead to therapeutic ineffectiveness. 
The lack of standardization of the number of drops per mL of 
solutions produced in magistral pharmacies may have been a 
factor affecting the dose quantities. Different alcohol degrees 
at different temperature significantly change the volume of a 
drop, making it necessary to standardize cannulas to ensure 
accuracy during use [18]. Since the magistral solutions 
contain a high amount of ethanol, the amount of drops per mL 
changes according to the percentage of the constituent and 
also according to the other inputs present in the formula. The 
magistral product A presented a greater volume from 20 
drops than the solutions B and C, which have greater amount 
of ethanol in their formulations.  
Figure 1: Volume of minoxidil topical solution to be applied on the 
scalp according to the indicated dosage (A= magistral sample A, B= 
magistral sample B, C= magistral sample C, Reference = industrial 
reference product). All samples were statistically different from the 
reference. 
 
In vitro follicular penetration of minoxidil 
 
Aiming clinical efficacy, topically applied drugs or cosmetic 
actives depend not only on their pharmacological properties, 
but also on their release from the vehicle, their penetration 
into the stratum corneum or other skin layers as well as their 
availability at the site of action [19]. Minoxidil, when applied 
topically, should permeate the percutaneous layer, but it 
should not permeate the entire skin, only reach the follicle 
bulb, thus preventing it from reaching the bloodstream. The 
minoxidil topical solutions used in this study were tested to 
assess the potential for follicular penetration of the active and 
the results are described in Figure 2. The results were 
calculated by discounting the value obtained for the placebo 
from the values obtained for the samples. 
Figure 2. Evaluation of in vitro follicular penetration of minoxidil 
from topical solutions (A= magistral sample A, B= magistral sample 
B, C= magistral sample C, Reference = industrial reference product). 
All samples were statistically equal to the reference. 
 
Comparing the follicular penetration of minoxidil applied 
from the magistral topical solutions with the reference 
sample, there are no significant differences (Figure 2). The 
low number of replicates and the high variability of such skin 
experiment may have contributed to the lack of statistical 
difference. Therefore, in the conditions of evaluation, the 
magistral topical solutions were able to promote the follicular 
penetration of minoxidil in a similar way as the reference 
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product, even though the magistral products A and B 
presented below-labeled drug content.  
Although no differences were found in the present 
investigation, it should be taken into account that, some 
factors, besides the lower drug content, may harm the 
minoxidil skin permeation or penetration into the hair 
follicles when in normal use conditions, considering the 
magistral samples. One of them is the considerable lower 
dosage indication (Figure 1), which was not considered in this 
experiment, since all donor compartments received the same 
volume of different topical solutions containing minoxidil. 
The other factor is the higher amount of ethanol, which 
increases the tendency of the drug to revert to an insoluble 
crystalline form when ethanol evaporates, thus possibly 
affecting it’s absorption through the skin [20]. At last, it 
should be considered that minoxidil sulfate, when solubilized, 
becomes ionized, presenting probably lower capacity of 
transcutaneous absorption compared to minoxidil base. 
Several studies have been devoted to the development of 
formulations aiming to increase minoxidil skin permeation 
and/or penetration into the hair follicles. Pereira and co-
workers (2016) developed solid effervescent formulation of 
minoxidil sulfate, demonstrating an increase in the drug 
permeation highly dependent on the concentration of the 
effervescent mixture in the formulation [21]. Mura and co-
workers (2013) studied the influence of penetration 
enhancing vesicles on transdermal minoxidil administration. 
In vitro diffusion experiments confirmed that vesicle 
formulations with penetration enhancers promoted greater 
drug deposition on the skin [22]. Matos and co-workers 
(2015) described that chitosan nanoparticles increased 
approximately 2 fold the penetration of minoxidil sulfate into 
the hair follicles, compared to the control [23]. Abd and co-
workers (2018) developed nanoemulsions containing 
eucalyptol or oleic acid, which enhanced the skin permeation 
of minoxidil, besides increasing the deposition of the 
substance in the hair follicles [24]. 
Conclusions  
 
The minoxidil topical solutions from magistral pharmacies 
presented differences compared to the industrial product in 
the quality parameters evaluated. Regarding the differences 
that can directly influence the efficacy and safety, the lower 
pH, the lower minoxidil content, and the lower indication of 
dosage to be applied in the hair follicles should be pointed 
out. Regarding in vitro follicular penetration, however, no 
statistical differences were found. 
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